Source-grounded facts extracted from MARIMED INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MARIMED INC.: Filed a Second Amended and Restated Certificate of Designation to designate the rights and preferences of the New Series B Preferred Stock (effective 2026-02-26).
“On February 26, 2026, in connection with the Loan Restructuring Transaction, the Company filed a Second Amended and Restated Certificate of Designation to designate the rights and preferences of the New Series B Preferred Stock with the Secretary of State of Delaware.”
MARIMED INC. incurred senior notes of principal amount of $6,000,000 with Navy Capital Green International, Ltd. and its affiliates at 10.0% per annum maturing March 1, 2031.
“the Company issued to Navy (i) two new promissory notes in the aggregate principal amount of $8,000,000, one in the principal amount of $2,000,000, due March 1, 2028, accruing interest at a rate of 8.0% per annum ("Note #1") and the other in the principal amount of $6,000,000, due March 1, 2031, accruing interest at a rate of 10.0% per annum (subject to reduction to 8% if Note #1 is paid in full within six (6) months of February 24, 2026) ("Note #2" collectively with Note #1, the "New Notes")”
MARIMED INC. incurred senior notes of aggregate principal amount of $8,000,000 with Navy Capital Green International, Ltd. and its affiliates at 8.0% per annum maturing March 1, 2028.
“the Company issued to Navy (i) two new promissory notes in the aggregate principal amount of $8,000,000, one in the principal amount of $2,000,000, due March 1, 2028, accruing interest at a rate of 8.0% per annum ("Note #1")”
MARIMED INC. entered into Restructuring and Exchange Agreement with Navy Capital Green International, Ltd. valued at $8,000,000 (effective 2026-02-24).
“On February 24, 2026, the Company and Navy entered into a Restructuring and Exchange Agreement (the “Restructuring and Exchange Agreement”) to address and restructure the Series B Obligation”
Mario Pinho was appointed as Chief Financial Officer at MARIMED INC..
“Effective August 9, 2024, MariMed Inc. (the “Company”) appointed Mario Pinho as the Company's Chief Financial Officer to replace Jon Levine, the Company's Interim Chief Financial Officer.”
MARIMED INC. reported the first quarter ended March 31, 2024 results: revenue $ 37.9, net income $ (1.3).
“1 The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts): Three months ended March 31, 2024 2023 Revenue $ 37.9 $ 34.4 GAAP Gross margin 43 % 45 % Non-GAAP Gross margin 44 % 46 % GAAP Net loss $ (1.3) $ (0.7) Non-GAAP Net (loss) income $ (0.6) $ 0.3 Non-GAAP Adjusted EBITDA $ 4.7 $ 7.1”
MARIMED INC. reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 6, 2024, MariMed Inc. (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, announcing its financial results for the three months and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.